Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsLaxmicotspin

    Jump to

    • Lupin sees more development on NeuClone deal in 5-6 qtrs

      S Ramesh, CFO of Lupin, in an interview with CNBC-TV18’s Latha Venkatesh and Gautam Broker, said that this agreement might bear fruit in five-six quarters. He also stated that Lupin wants a positive development in this particular area.

    • Expect to improve EBITDA margin by 75 bps ahead: Lupin

      Lupin has declared its fourth quarter results. Kamal K Sharma, MD, Lupin says, the company’s endeavour would be to grow around 25% year-on-year (YoY) on organic basis, unless it makes some inorganic moves that could be additive. “Our attempt has always been to improve on EBITDA margins by atleast 75 bps,” he adds.

    • No quantifiable impact seen in Japan operations: Lupin

      In an interview with CNBC-TV18,Vinod Dhawan, president- business development of Lupin said, "All our personnel are fine and the facilities are working normally so there isn't much impact in this area."

    • Govt should focus on sustenance of EOUs: Lupin

      Drug firm Lupin is optimistic about performing well in the next fiscal says S Ramesh, chief financial officer of the company. The company aims to maintain 20% growth rate in the next year as well.

    • What is Lupin's acquisition agenda for the future?

      Kamal Sharma, Managing Director of Lupin, started four decades ago almost as a stockiest and C&F agent. Today, his company is one of India’s largest drug manufacturers and the 5th largest generic drug manufacturer in the world.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347